315 research outputs found
A comparative molecular field and comparative molecular similarity indices analyses (CoMFA and CoMSIA) of N-phenyl-N'-(2-chloroethyl)urea targeting the colchicine-binding site as anticancer agents
To decipher the mechanism underlying the covalent binding of N-phenyl-N′-(2-chloroethyl)ureas (CEU) to the colchicine-binding site on βII-tubulin and to design new and selective antimitotic drugs, we developed 3D quantitative structure–activity relationships (3D-QSAR) models using CoMFA and CoMSIA analyses. The present study correlates the cell growth inhibition activities of 56 structurally related CEU derivatives to several physicochemical parameters representing steric, electrostatic, and hydrophobic fields. Both CoMFA and CoMSIA models using two different optimum numbers of components (ONC) 10 and 4, respectively, gave good internal predictions and their cross-validated r2 values were between 0.639 and 0.743. These comprehensive CoMFA and CoMSIA models are useful in understanding the structure–activity relationships of CEU. The two models were compared to the X-ray crystal structure of the complex of tubulin–colchicine and analyzed for similarities between the two modes of analysis. These models will inspire the design of new CEU derivatives with enhanced inhibition of tumor cell growth and targeting specificity of βII-tubulin and the cytoskeleton
Constraining the nuclear equation of state at subsaturation densities
Only one third of the nucleons in Pb occupy the saturation density
area. Consequently nuclear observables related to average properties of nuclei,
such as masses or radii, constrain the equation of state (EOS) not at
saturation density but rather around the so-called crossing density, localised
close to the mean value of the density of nuclei: 0.11 fm.
This provides an explanation for the empirical fact that several EOS quantities
calculated with various functionals cross at a density significantly lower than
the saturation one. The third derivative M of the energy at the crossing
density is constrained by the giant monopole resonance (GMR) measurements in an
isotopic chain rather than the incompressibility at saturation density. The GMR
measurements provide M=1110 70 MeV (6% uncertainty), whose extrapolation
gives K=230 40 MeV (17% uncertainty).Comment: 4 pages, 4 figure
Linking Two Immuno-Suppressive Molecules: Indoleamine 2,3 Dioxygenase Can Modify HLA-G Cell-Surface Expression1
Nonclassical human leukocyte antigen (HLA) class I molecule
HLA-G and indoleamine 2,3 dioxygenase (INDO) in humans and
mice, respectively, have been shown to play crucial immunosuppressive
roles in fetal-maternal tolerance. HLA-G inhibits
natural killer and T cell function by high-affinity interaction with
inhibitory receptors, and INDO acts by depleting the surrounding
microenvironment of the essential amino acid tryptophan,
thus inhibiting T cell proliferation. We investigated whether
HLA-G expression and INDO function were linked. Working
with antigen-presenting cell (APC) lines and monocytes, we
found that functional inhibition of INDO by 1-methyl-tryptophan
induced cell surface expression of HLA-G1 by HLA-G1-
negative APCs that were originally cell-surface negative, and
that in reverse, the functional boost of INDO by high concentrations
of tryptophan induced a complete loss of HLA-G1 cell
surface expression by APCs that were originally cell-surface
HLA-G1-positive. This mechanism was shown to be posttranslational
because HLA-G protein cell contents remained unaffected
by the treatments used. Furthermore, HLA-G cell surface
expression regulation by INDO seems to relate to INDO function,
but not to tryptophan catabolism itself. Potentia
Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1
© The Author(s) 2018.The association between depth of response in multiple myeloma (MM) and long-term outcomes is well recognized [1,2,3]. Thus, clinicians and patients are often encouraged by a rapid decrease of M-protein when treatment is initiated, and achieving ≥very-good partial response (VGPR) by 4 months of initial diagnosis has been associated with decreased mortality [4]. However, little is known about the association between response kinetics and outcomes. While some reports suggest that early responders may have compromised long-term outcomes compared with late responders [5, 6], these studies were limited, confined to frontline setting only, and based in the era prior to novel-agent availability.TOURMALINE-MM1 was sponsored by Millennium Pharmaceuticals Inc. Writing assistance for this manuscript was provided by Jane Saunders, FireKite (an Ashfield Company, part of UDG Healthcare PLC) and was funded by Millennium Pharmaceuticals Inc
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Substantial improvements in survival have been seen in multiple myeloma (MM) over recent years, associated with the
introduction and widespread use of multiple novel agents and regimens, as well as the emerging treatment paradigm
of continuous or long-term therapy. However, these therapies and approaches may have limitations in the community
setting, associated with toxicity burden, patient burden, and other factors including cost. Consequently, despite
improvements in efficacy in the rigorously controlled clinical trials setting, the same results are not always achieved in
real-world practice. Furthermore, the large number of different treatment options and regimens under investigation in
various MM settings precludes the feasibility of obtaining head-to-head clinical trial data, and there is a temptation to
use cross-trial comparisons to evaluate data across regimens. However, multiple aspects, including patient-related,
disease-related, and treatment-related factors, can influence clinical trial outcomes and lead to differences between
studies that may confound direct comparisons between data. In this review, we explore the various factors requiring
attention when evaluating clinical trial data across available agents/regimens, as well as other considerations that may
impact the translation of these findings into everyday MM management. We also investigate discrepancies between
clinical trial efficacy and real-world effectiveness through a literature review of non-clinical trial data in relapsed/
refractory MM on novel agent−based regimens and evaluate these data in the context of phase 3 trial results for
recently approved and commonly used regimens. We thereby demonstrate the complexity of interpreting data across
clinical studies in MM, as well as between clinical studies and routine-care analyses, with the aim to help clinicians
consider all the necessary issues when tailoring individual patients’ treatment approaches
Bartonella quintana coinfection with Mycobacterium avium complex and CMV in an AIDS patient: case presentation
BACKGROUND: As a greater number of HIV-infected patients survive despite profound immunodepression due to medical progress, we face complex infection with multiple agents in AIDS-patients. CASE PRESENTATION: We report the case of an AIDS patient with a primary clinical presentation suggestive of bacillary angiomatosis. We also found in cutaneous lesions Mycobacterium avium complex and cytomegalovirus. CONCLUSION: This clinical case illustrates the possibility of multiple coinfections in AIDS patients and the need to be exhaustive in evaluating infectious diseases in severely immunocompromised patients
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group
Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders
Daratumumab plus lenalidomide and dexamethasone in relapsed/ refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of disease progression or death by 63% and increased the overall response rate (ORR) versus Rd in relapsed/refractory multiple myeloma (RRMM). Updated efficacy and safety after >3 years of follow-up are presented. Patients (N = 569) with ≥1 prior line received Rd (lenalidomide, 25 mg, on Days 1–21 of each 28-day cycle; dexamethasone, 40 mg, weekly) ± daratumumab at the approved dosing schedule. Minimal residual disease (MRD) was assessed by next-generation sequencing. After 44.3 months median follow-up, D-Rd prolonged progression-free survival (PFS) in the intent-to-treat population (median 44.5 vs 17.5 months; HR, 0.44; 95% CI, 0.35–0.55; P < 0.0001) and in patient subgroups. D-Rd demonstrated higher ORR (92.9 vs 76.4%; P < 0.0001) and deeper responses, including complete response or better (56.6 vs 23.2%; P < 0.0001) and MRD negativity (10–5; 30.4 vs 5.3%; P < 0.0001). Median time to next therapy was prolonged with D-Rd (50.6 vs 23.1 months; HR, 0.39; 95% CI, 0.31–0.50; P < 0.0001). Median PFS on subsequent line of therapy (PFS2) was not reached with D-Rd versus 31.7 months with Rd (HR, 0.53; 95% CI, 0.42–0.68; P < 0.0001). No new safety concerns were reported. These data support using D-Rd in patients with RRMM after first relapse
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project
Purpose: multiple myeloma is considered an incurable hematologic cancer but a subset of patients can achieve long-term remissions and survival. The present study examines the clinical features of long-term survival as it correlates to depth of disease response. Patients & Methods: this was a multi-institutional, international, retrospective analysis of high-dose melphalan-autologous stem cell transplant (HDM-ASCT) eligible MM patients included in clinical trials. Clinical variable and survival data were collected from 7291 MM patients from Czech Republic, France, Germany, Italy, Korea, Spain, the Nordic Myeloma Study Group and the United States. Kaplan–Meier curves were used to assess progression-free survival (PFS) and overall survival (OS). Relative survival (RS) and statistical cure fractions (CF) were computed for all patients with available data. Results: achieving CR at 1 year was associated with superior PFS (median PFS 3.3 years vs. 2.6 years, p < 0.0001) as well as OS (median OS 8.5 years vs. 6.3 years, p < 0.0001). Clinical variables at diagnosis associated with 5-year survival and 10-year survival were compared with those associated with 2-year death. In multivariate analysis, age over 65 years (OR 1.87, p = 0.002), IgA Isotype (OR 1.53, p = 0.004), low albumin < 3.5 g/dL (OR = 1.36, p = 0.023), elevated beta 2 microglobulin ≥ 3.5 mg/dL (OR 1.86, p < 0.001), serum creatinine levels ≥ 2 mg/dL (OR 1.77, p = 0.005), hemoglobin levels < 10 g/dL (OR 1.55, p = 0.003), and platelet count < 150k/μL (OR 2.26, p < 0.001) appeared to be negatively associated with 10-year survival. The relative survival for the cohort was ~0.9, and the statistical cure fraction was 14.3%. Conclusions: these data identify CR as an important predictor of long-term survival for HDM-ASCT eligible MM patients. They also identify clinical variables reflective of higher disease burden as poor prognostic markers for long-term survival
- …